BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 23380027)

  • 1. Parkinson disease: from pathology to molecular disease mechanisms.
    Dexter DT; Jenner P
    Free Radic Biol Med; 2013 Sep; 62():132-144. PubMed ID: 23380027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
    Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
    J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial dysfunction in genetic animal models of Parkinson's disease.
    Trancikova A; Tsika E; Moore DJ
    Antioxid Redox Signal; 2012 May; 16(9):896-919. PubMed ID: 21848447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease.
    Ryan BJ; Hoek S; Fon EA; Wade-Martins R
    Trends Biochem Sci; 2015 Apr; 40(4):200-10. PubMed ID: 25757399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease.
    Yan MH; Wang X; Zhu X
    Free Radic Biol Med; 2013 Sep; 62():90-101. PubMed ID: 23200807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease.
    Thomas B; Beal MF
    Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R183-94. PubMed ID: 17911161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease.
    McNaught KS; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S73-84; discussion S84-6. PubMed ID: 12666100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein.
    Ciron C; Zheng L; Bobela W; Knott GW; Leone TC; Kelly DP; Schneider BL
    Acta Neuropathol Commun; 2015 Apr; 3():16. PubMed ID: 25853296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
    Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
    J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathological mechanisms of Parkinson's disease].
    Matsui H; Takahashi R
    Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.
    Ferrer I; Martinez A; Blanco R; Dalfó E; Carmona M
    J Neural Transm (Vienna); 2011 May; 118(5):821-39. PubMed ID: 20862500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
    McNaught KS; Jnobaptiste R; Jackson T; Jengelley TA
    Synapse; 2010 Mar; 64(3):241-50. PubMed ID: 19924695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
    Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
    Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.
    Mudò G; Mäkelä J; Di Liberto V; Tselykh TV; Olivieri M; Piepponen P; Eriksson O; Mälkiä A; Bonomo A; Kairisalo M; Aguirre JA; Korhonen L; Belluardo N; Lindholm D
    Cell Mol Life Sci; 2012 Apr; 69(7):1153-65. PubMed ID: 21984601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.